Bayer's Financial Overview

Bayer AG disclosed its financial performance for the fourth quarter of fiscal 2024, revealing a slight decrease in sales to €11.7 billion, marking a 1% drop. The full-year figures also saw a decline, with sales falling by 2.2% to €46.6 billion.

EBITDA and Net Income Insights

The company reported an EBITDA of €1.9 billion for the quarter and €8.7 billion for the year. Despite the challenges, Bayer's net income showed improvement from the previous quarter, standing at €1.3 billion or €1.36 per share. However, the fiscal year concluded with a net loss of €2.9 billion or €2.99 per share.

Future Outlook and Challenges

Looking ahead, Bayer anticipates its net sales for the full year of 2025 to range between €45 and €47 billion. The report also highlights concerns over geopolitical uncertainties, including potential tariffs and foreign exchange fluctuations, which could impact future performance.

Strategic Focus and Conclusion

"2024 was a challenging year for Bayer, characterized by volatile business dynamics. The Supervisory Board concentrated on strategic alignment and addressing key issues, such as ongoing litigations in the United States, the company's high leverage ratio, and the development of the pharmaceutical pipeline," the report concluded.